Merit Cudkowicz

Active 1977–2026

155
Papers
23,594
Citations
91
h-index
147
i10-index

Citations

Citations per year for Merit Cudkowicz1930: 1 citations1951: 3 citations1977: 2 citations1991: 3 citations1992: 4 citations1993: 3 citations1994: 1 citations1995: 8 citations1996: 3 citations1997: 8 citations1998: 16 citations1999: 29 citations2000: 30 citations2001: 47 citations2002: 63 citations2003: 73 citations2004: 87 citations2005: 106 citations2006: 122 citations2007: 143 citations2008: 170 citations2009: 174 citations2010: 160 citations2011: 173 citations2012: 150 citations2013: 216 citations2014: 251 citations2015: 249 citations2016: 299 citations2017: 324 citations2018: 277 citations2019: 827 citations2020: 965 citations2021: 928 citations2022: 1,012 citations2023: 858 citations2024: 1,267 citations2025: 568 citations2026: 21 citations1931–1950: no citations, so these years are not shown1952–1976: no citations, so these years are not shown1978–1990: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,241 citing papers, 29.4% of this breakdownUnited Kingdom: 938 citing papers, 8.5% of this breakdownItaly: 732 citing papers, 6.6% of this breakdownGermany: 598 citing papers, 5.4% of this breakdownChina: 560 citing papers, 5.1% of this breakdownCanada: 455 citing papers, 4.1% of this breakdownAustralia: 411 citing papers, 3.7% of this breakdownFrance: 396 citing papers, 3.6% of this breakdownNetherlands: 337 citing papers, 3.1% of this breakdownSpain: 306 citing papers, 2.8% of this breakdownJapan: 252 citing papers, 2.3% of this breakdownSwitzerland: 212 citing papers, 1.9% of this breakdown
0%29.4%Other 23.5%

Fields

  • Medicine53.7%
  • Neuroscience17.2%
  • Biochemistry, Genetics and Molecular Biology16.4%
  • Health Professions3.9%
  • Engineering1.8%
  • Computer Science1.5%
  • Other5.5%

Topics

  • Amyotrophic Lateral Sclerosis Research12.5%
  • Neurogenetic and Muscular Disorders Research7.7%
  • Genetic Neurodegenerative Diseases4.8%
  • Parkinson's Disease Mechanisms and Treatments4.3%
  • Neuroinflammation and Neurodegeneration Mechanisms2.9%
  • Alzheimer's disease research and treatments2.8%
  • Other65%

Coauthors

All papers

Open in search
  1. Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2022 cited by 850

  2. Trial of Sodium Phenylbutyrate–Taurursodiol for Amyotrophic Lateral Sclerosis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Patricia L. Andres, Suma Babu, Marianne Chase, Derek D’Agostino, Samuel P. Dickson, Noel Ellison, Meghan Hall, Kent Hendrix, Gale Kittle, Michelle McGovern, Joseph Ostrow, Lindsay Pothier, Rebecca Randall, Jeremy M. Shefner, Alexander Sherman, Eric Tustison, Prasha Vigneswaran, Jason Walker, Hong Yu, James Chan, Janet Wittes, Joshua Cohen, Justin Klee, Kent Leslie, Rudolph E. Tanzi, Walter Gilbert, Patrick Yeramian, David Schoenfeld, Merit Cudkowicz - New England Journal of Medicine 2020 cited by 524

  3. Phase 1–2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Toby A. Ferguson - New England Journal of Medicine 2020 cited by 543

  4. SOD1 Suppression with Adeno-Associated Virus and MicroRNA in Familial ALS

    Authors: , , , , , , , , , , , , , , , - New England Journal of Medicine 2020 cited by 252

  5. Improving clinical trial outcomes in amyotrophic lateral sclerosis

    Authors: , , , , , , , , , , , , , , - Nature Reviews Neurology 2020 cited by 291

  6. Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models

    Authors: , , , , , , , , , , , , , , , , , , , - Journal of Clinical Investigation 2018 cited by 272

  7. Answer ALS, a large-scale resource for sporadic and familial ALS combining clinical and multi-omics data from induced pluripotent cell lines

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Michael J. Workman, Ritchie Ho, Stacia K. Wyman, Jennifer Roggenbuck, Matthew B. Harms, Jennifer Stocksdale, Ricardo Miramontes, Keona Q. Wang, Vidya Venkatraman, Ronald Holewenski, Niveda Sundararaman, Rakhi Pandey, Danica-Mae Manalo, Aneesh Donde, Nhan Huynh, Miriam Adam, Brook T. Wassie, Edward Vertudes, Naufa Amirani, Krishna Raja, Reuben Thomas, Lindsey R. Hayes, Alex Lenail, Aianna Cerezo, Sarah Luppino, Alanna Farrar, Lindsay Pothier, Carolyn Prina, Todd E. Morgan, Arish Jamil, Sarah Heintzman, Jennifer Jockel‐Balsarotti, Elizabeth Karanja, Jesse Markway, Molly McCallum, Ben Joslin, Deniz Alibazoglu, Stephen J. Kolb, Senda Ajroud‐Driss, Robert H. Baloh, Daragh Heitzman, T. W. Miller, Jonathan D. Glass, Natasha Leanna Patel-Murray, Hong Yu, Ervin Sinani, Prasha Vigneswaran, Alexander Sherman, Omar Ahmad, Promit Roy, Jay Beavers, Steven R. Zeiler, John W. Krakauer, Carla Agurto, Guillermo Cecchi, Mary Bellard, Yogindra Raghav, Karen Sachs, Tobias Ehrenberger, Elizabeth Bruce, Merit Cudkowicz, Nicholas J. Maragakis, Raquel Norel, Jennifer E. Van Eyk, Steven Finkbeiner, James D. Berry, Dhruv Sareen, Leslie M. Thompson, Ernest Fraenkel, Clive N. Svendsen and 1 more - Nature Neuroscience 2022 cited by 158

  8. Natural history of infantile‐onset spinal muscular atrophy

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Vicki L. McGovern, Xueqian Wang, Phillip G. Zaworski, Thomas W. Prior, Arthur H.M. Burghes, Amy Bartlett, John T. Kissel - Annals of Neurology 2017 cited by 409

  9. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study

    Authors: , , , , , , , , , , , , , , , , , , , - The Lancet Neurology 2013 cited by 607

  10. Identification of Therapeutic Targets for Amyotrophic Lateral Sclerosis Using PandaOmics – An AI-Enabled Biological Target Discovery Platform

    Authors: , , , , , , , , , , , , , , , , , , , - Frontiers in Aging Neuroscience 2022 cited by 99

  11. Long‐term survival of participants in the CENTAUR trial of sodium phenylbutyrate‐taurursodiol in amyotrophic lateral sclerosis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Namita Goyal, Gary L. Pattee, Patricia L. Andres, Suma Babu, Marianne Chase, Derek D’Agostino, Meghan Hall, Gale Kittle, Matthew Eydinov, Michelle McGovern, Joseph Ostrow, Lindsay Pothier, Rebecca Randall, Jeremy M. Shefner, Alexander Sherman, Maria E. St. Pierre, Eric Tustison, Prasha Vigneswaran, Jason Walker, Hong Yu, James Chan, Janet Wittes, Zi‐Fan Yu, Joshua Cohen, Justin Klee, Kent Leslie, Rudolph E. Tanzi, Walter Gilbert, Patrick Yeramian, David Schoenfeld, Merit Cudkowicz - Muscle & Nerve 2020 cited by 180

  12. Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Enrique Álvarez, Michelle Apperson, Khurram Bashir, Bruce A. Cohen, Patricia K. Coyle, Silvia Delgado, L. Dana DeWitt, Angela Flores, Barbara S. Giesser, Myla Goldman, Burk Jubelt, Neil Lava, Sharon Lynch, Harold L. Moses, Daniel Ontaneda, Jai Perumal, Michael K. Racke, Pavle Repovic, Claire Riley, Christopher Severson, Shlomo Shinnar, Valerie Suski, Bianca Weinstock-Guttman, Vijayshree Yadav, Aram Zabeti - New England Journal of Medicine 2018 cited by 285

  13. Intrinsic Membrane Hyperexcitability of Amyotrophic Lateral Sclerosis Patient-Derived Motor Neurons

    Authors: , , , , , , , , , , , , , , , - Cell Reports 2014 cited by 686

  14. A randomized placebo‐controlled phase 3 study of mesenchymal stem cells induced to secrete high levels of neurotrophic factors in amyotrophic lateral sclerosis

    Authors: , , , , , , , , , , , , , , , , , , , , - Muscle & Nerve 2021 cited by 114

  15. Gait variability and basal ganglia disorders: Stride‐to‐stride variations of gait cycle timing in parkinson's disease and Huntington's disease

    Authors: , , , , - Movement Disorders 1998 cited by 904

  16. Modulating inflammatory monocytes with a unique microRNA gene signature ameliorates murine ALS

    Authors: , , , , , , , , , , , , , , - Journal of Clinical Investigation 2012 cited by 474

  17. Targeting miR‐155 restores abnormal microglia and attenuates disease in SOD1 mice

    Authors: , , , , , , , , , , , , , , , , , , , - Annals of Neurology 2014 cited by 359

  18. Effect of Ezogabine on Cortical and Spinal Motor Neuron Excitability in Amyotrophic Lateral Sclerosis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Adel Marei, Peter B. Rosenquist, Sean K. Meehan, Björn Oskarsson, Richard A. Lewis, Divpreet Kaur, Evangelos Kiskinis, Clifford J. Woolf, Kevin Eggan, Michael D. Weiss, James D. Berry, William S. David, Paula Davila-Pérez, Joan A. Camprodon, Álvaro Pascual‐Leone, Matthew C. Kiernan, Jeremy M. Shefner, Nazem Atassi, Merit Cudkowicz - JAMA Neurology 2020 cited by 139

  19. Artificial intelligence in neurology: opportunities, challenges, and policy implications

    Authors: , , , , , , , , , , , , , , - Journal of Neurology 2024 cited by 84

  20. Dynamic markers of altered gait rhythm in amyotrophic lateral sclerosis

    Authors: , , , , , - Journal of Applied Physiology 2000 cited by 495

  21. Expanded autologous regulatory T-lymphocyte infusions in ALS

    Authors: , , , , , , , - Neurology Neuroimmunology & Neuroinflammation 2018 cited by 191

  22. Adaptive Platform Trials to Transform Amyotrophic Lateral Sclerosis Therapy Development

    Authors: , , , , , , , , , , , , , , , - Annals of Neurology 2021 cited by 81

  23. Sodium phenylbutyrate prolongs survival and regulates expression of anti‐apoptotic genes in transgenic amyotrophic lateral sclerosis mice

    Authors: , , , , , , , , , , - Journal of Neurochemistry 2005 cited by 352

  24. The PRO-ACT database

    Authors: , , , , , , , , , , - Neurology 2014 cited by 289